|
|
|
20.10.25 - 07:12
|
Novo Nordisk nach dem Trump-Schock – das sagen JPMorgan & Co (Der Aktionaer)
|
|
|
Die Aktien von Novo Nordisk und Eli Lilly standen am Freitag deutlich unter Druck. Grund waren Äußerungen von US-Präsident Donald Trump zu den Preisen von Abnehmpräparaten. Er Erklärte der Preis für eine Monatsration des Abnehmmittels Ozempic von Novo Nordisk könnte von derzeit mehr als 1....
|
|
|
|
|
|
|
|
|
18.10.25 - 00:24
|
Novo, Lilly Fall as Trump Touts ′Much Lower′ Ozempic Price (Bloomberg)
|
|
|
Novo Nordisk and Eli Lilly shares fell after President Donald Trump said the price of the blockbuster diabetes drug Ozempic could come down to just $150 a month.
The US list price of Ozempic, which Trump called “the fat loss drug,” is roughly $1,000 for a month's supply. Trump told reporters on Thursday that the cost of the drug, made by Novo, will soon be “much lower.” Lilly sells similar treatments, including Mounjaro and Zepbound. “Those are going to be $150 out of pocket,” he said during a press conference in the Oval Office. That could lead to a big hit for Novo and Lilly, the two companies dominating the market Wall Street expects to top $95 billion by 2030. Bloomberg News Health Reporter Madison Muller joins Bloomberg Businessweek Daily to discuss. She speaks with Carol Massar and Bailey Lipschultz. (Source: Bloomberg)...
|
|
|
|
|
17.10.25 - 19:18
|
Loan Fraud Hits Zions, Western Alliance | Open Interest 10/17/2025 (Bloomberg)
|
|
|
Get a jump start on the US trading day with Matt Miller and Dani Burger on "Bloomberg Open Interest." President Trump dials down fears of a trade war with China, saying tariffs on Beijing aren't sustainable. And traders get SVB flashbacks as two regional lenders fuel fears about problems in credit markets. Plus: President Trump is making Ozempic cheaper. Good news for users, but not so great for drugmakers Eli Lilly and Novo Nordisk. (Source: Bloomberg)...
|
|
|
|
|
|
|
17.10.25 - 17:36
|
Is Trump Going to Kill the GLP-1 Cash Cow? (24/7 Wall St.)
|
|
|
The Boom That Built Billion-Dollar Empires GLP-1 drugs have reshaped the pharmaceutical landscape, turning obesity and diabetes treatments into massive revenue streams for Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY). These medications, including NVO's Ozempic and Wegovy, and LLY's Mounjaro and Zepbound, mimic hormones to curb appetite and regulate blood sugar. Their popularity exploded in ... Is Trump Going to Kill the GLP-1 Cash Cow?
The post Is Trump Going to Kill the GLP-1 Cash Cow? appeared first on 24/7 Wall St.....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17.10.25 - 12:36
|
Lilly, Novo Slide as Trump Touts Lower Ozempic Price (Bloomberg)
|
|
|
President Donald Trump said the price of the diabetes drug Ozempic will soon be “much lower” and could come down to just $150 a month, pushing shares of Novo Nordisk A/S and Eli Lilly & Co. lower. Sam Fazeli of Bloomberg Intelligence has more....
|
|
|
|
|
17.10.25 - 10:18
|
Novo Nordisk und Eli Lilly unter Druck – Trump will massiven Preissturz (Der Aktionaer)
|
|
|
Die Aktien von Novo Nordisk und Eli Lilly stehen zum Wochenschluss deutlich unter Druck. Knapp vier beziehungsweise gut vier Prozent geht es bei den Werten auf der Handelsplattform Tradegate am Freitagvormittag nach unten. Auslöser waren Aussagen von US-Präsident Trump, der Preissenkungen für Abnehmmedikamente in Aussicht stellte....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
